Clinical Trials

130 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03349450 2026-05-06

SPiReL

25 enrolled 18 charts

LymphoidSarcoma

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT03752333 2026-05-04

CUPem

35 enrolled 11 charts

Carcinoma, Neoplasms, Neoplasms, Unknown Primary

NCT05064280 2026-04-16

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

104 enrolled

CNS

Brain Neoplasms, Neoplasms

NCT04847466 2026-04-08

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

18 enrolled

Neoplasms

NCT03505320 2026-04-03

ILUSTRO

143 enrolled

Neoplasms, Stomach Neoplasms

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

GastrointestinalHead & Neck

7 enrolled 14 charts

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02769520 2026-01-28

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

27 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT04795661 2026-01-07

IMHOTEP

240 enrolled

Neoplasms

NCT06116578 2025-12-01

NeoSarc

Sarcoma

Liposarcoma, Neoplasms, Sarcoma

NCT04964960 2025-10-31

Pembro+Chemo in Brain Mets

Phase 2 Terminated

3 enrolled 7 charts

CNSThoracic

Brain Neoplasms, Lung Neoplasms, Neoplasms

NCT03383094 2025-10-07

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

126 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT05271604 2025-09-26

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

42 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT06831136 2025-09-10

PANCARDINAL-2

24 enrolled

Neoplasm Metastasis, Neoplasms

NCT05304546 2025-07-22

MK3475-C01

1 enrolled

Dermatologic

Melanoma, Neoplasms

NCT04830124 2025-06-10

ARTISTRY-6

Phase 2 Terminated

173 enrolled

Dermatologic

Melanoma, Neoplasms

NCT04976634 2025-04-06

MK-6482-016

730 enrolled

Neoplasms

NCT03632941 2025-03-12

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

8 enrolled 13 charts

Breast

Breast Neoplasms, Neoplasms

NCT04144517 2024-10-16

A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

14 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT04510636 2024-03-22

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

37 enrolled

Neoplasms, Recurrence

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Neoplasms

NCT03308942 2023-10-16

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

53 enrolled 35 charts

Neoplasms

NCT02858921 2023-08-30

Neo Trio

Phase 2 Unknown

60 enrolled

Dermatologic

Melanoma, Neoplasms

NCT04258683 2023-08-29

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Plasma cell

Cardiovascular Diseases, Hematologic Diseases, Immune System Diseases, Multiple Myeloma, Neoplasms

NCT05281003 2023-07-13

HYPERION

128 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Hypoxia, Digestive System Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

GastrointestinalGynecologic

24 enrolled

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

NCT03276013 2021-10-05

TOPIC

48 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT02798406 2021-07-15

CAPTIVE

49 enrolled

CNSSarcoma

Brain Neoplasms, Disease, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue, Nervous System Diseases, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Gliosarcoma

NCT03832673 2021-02-26

PECULIAR

Neoplasms

NCT02981524 2021-02-10

Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer

17 enrolled 12 charts

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Neoplasms, Neoplasms by Site, Rectal Diseases, Colorectal Neoplasms

NCT02423863 2020-12-17

Poly-ICLC

DermatologicHead & NeckSarcoma

26 enrolled

Head and Neck Neoplasms, Melanoma, Neoplasms, Sarcoma

NCT04016116 2020-05-27

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT03697824 2019-10-29

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Sarcoma

Neoplasms, Sarcoma, Synovial

NCT03634332 2019-05-07

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Phase 2 Unknown

35 enrolled